2008-02-13 Assigned to UNIVERSITE LOUIS PASTEUR DE STRASBOURG, LE CENTER
NATIONAL DE LA RECHERCHE SCIENTIFIQUE reassignment UNIVERSITE LOUIS …

Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells
(particularly leukemic and lymphomic cells) and pharmaceutical compositions containing …

Disclosed are macrocyclic compounds of formulae IV, which are analogs of the pochonin
resorcylic acid lactones, and processes for the preparation of the compounds. The …

The present invention provides PBP2a peptide antigens for generating antibodies against
MRSA, and provides high-af finity binding agents that detect MRSA by selective immu …

5,639,641 A 5,776,456 A 5,783,184 A 5,830,470 A 5,830,663 A 5,837,243 A 5,843,749 A
5,861,155 A 5,969,107 A 5,977,316 A 6,080,588 A 6,291,208 B1 6,309,636 B1 6,323,027 …

Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells
(particularly leukemic and lymphomic cells) and pharmaceutical compositions containing …

The invention concerns various methods of using labeled HSP90 inhibitors to improve
treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for …

The present invention describes inhibitors of extracellular Hsp90. The inhibition of
extracellular Hsp90 leads to a reduc tion of the invasiveness of the tumor cells. Furthermore …

FDDXEJWGEMZKBX-UHFFFAOYSA-N CC (C)(C) OC (N1CCC (CC [n] 2c (Sc (c (C= O) c3)
cc4c3OCO4) nc3c (N) ncnc23) CC1)= O Chemical compound CC (C)(C) OC (N1CCC (CC …

Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells
(particularly leukemic and lymphomic cells) and pharmaceutical compositions contain ing …